U.S. patent application number 12/403817 was filed with the patent office on 2009-07-16 for chimeric toxins for targeted therapy.
This patent application is currently assigned to Yissum Research Development Company of the Hebrew University of Jerusalem. Invention is credited to Haya Lorberboum-Galski, Irina Marianovsky, Amotz Nechushtan, Shai Yarkoni.
Application Number | 20090181894 12/403817 |
Document ID | / |
Family ID | 11068929 |
Filed Date | 2009-07-16 |
United States Patent
Application |
20090181894 |
Kind Code |
A1 |
Yarkoni; Shai ; et
al. |
July 16, 2009 |
CHIMERIC TOXINS FOR TARGETED THERAPY
Abstract
The present invention relates particularly to neoplastic cells
targeted chimeric toxins comprising of cell targeting moieties and
cell killing moieties for recognizing and for destroying the
neoplastic cells, wherein the cell targeting moieties consist of
gonadotropin releasing hormone homologues and the cell killing
moieties consist of Pseudomonas Exotoxin A. The present invention
further relates to pharmaceutical compositions containing as an
active ingredient these neoplastic cells targeted chimeric toxins
and to a method for the production of these chimeric toxins. The
said invention also relates to a method for cancer therapy,
treating malignant carcinoma cells and benign hyperplasia including
uterine leiomyoma cells, extrauterine endometrial island cells,
benign hyperplasia of prostate and breast and pituitary tumor
adenoma cells, by the use of the above-mentioned chimeric
toxins.
Inventors: |
Yarkoni; Shai; (Kfar Saba,
IL) ; Nechushtan; Amotz; (Aseret, IL) ;
Lorberboum-Galski; Haya; (Jerusalem, IL) ;
Marianovsky; Irina; (Jerusalem, IL) |
Correspondence
Address: |
VOLPE AND KOENIG, P.C.
UNITED PLAZA, SUITE 1600, 30 SOUTH 17TH STREET
PHILADELPHIA
PA
19103
US
|
Assignee: |
Yissum Research Development Company
of the Hebrew University of Jerusalem
Jerusalem
IL
|
Family ID: |
11068929 |
Appl. No.: |
12/403817 |
Filed: |
March 13, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11147360 |
Jun 8, 2005 |
|
|
|
12403817 |
|
|
|
|
09147346 |
Mar 1, 1999 |
6933271 |
|
|
PCT/IL97/00180 |
Dec 11, 1997 |
|
|
|
11147360 |
|
|
|
|
Current U.S.
Class: |
514/10.3 ;
435/320.1; 435/69.7; 530/350 |
Current CPC
Class: |
A61P 35/00 20180101;
A61K 47/549 20170801 |
Class at
Publication: |
514/12 ; 530/350;
435/69.7; 435/320.1 |
International
Class: |
A61K 38/16 20060101
A61K038/16; C07K 14/00 20060101 C07K014/00; C12P 21/00 20060101
C12P021/00; C12N 15/74 20060101 C12N015/74; A61P 35/00 20060101
A61P035/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 4, 1996 |
IL |
118570 |
Claims
1. A fused chimeric protein comprising a linear genetically
engineered peptide encoded by an oligonucleotide that includes A)
DNA encoding at least one cell targeting moiety consisting
essentially of Met-GnRH or a Met-GnRH analog that specifically
binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B)
DNA encoding at least one cell killing moiety; wherein the peptide
includes Met-GnRH or a Met-GnRH analog, and at least one cell
killing moiety.
2. A fused chimeric protein according to claim 1, wherein the DNA
encoding at least one cell killing moiety encodes a mutated full
length Pseudomonas exotoxin (PE).
3. A fused chimeric protein according to claim 1, wherein the DNA
encoding at least one cell killing moiety encodes a DNA fragment
comprising domains II and III of the Pseudomonas exotoxin (PE).
4. A method for the production of a fused chimeric protein as
defined in claim 2, comprising preparing the oligonucleotide by
ligating the DNA encoding Met-GnRH or a Met-GnRH analog upstream of
the DNA fragment encoding the mutated form of PE, and expressing
the oligonucleotide under conditions sufficient to produce the
fused chimeric protein.
5. A method for the production of a fused chimeric protein as
defined in claim 3, comprising preparing the oligonucleotide by
ligating the DNA encoding Met-GnRH or a Met-GnRH analog upstream to
the DNA fragment encoding domains II and III of PE, and expressing
the oligonucleotide under conditions sufficient to produce the
fused chimeric protein.
6. A composition useful for treatment in cancer therapy comprising
the fused chimeric protein as defined in claim 1.
7. A plasmid comprising a promoter operably linked to a DNA
molecule encoding a fused chimeric protein as defined in claim
1.
8. A chimeric protein comprising a genetically engineered molecule
comprising a fusion of at least one cell targeting moiety
consisting essentially of gonadotropin releasing hormone (GnRH)
preceded by a Met (Met-GnRH) or a Met-GnRH analog that specifically
binds to GnRH binding sites on Caco2 adenocarcinoma; and at least
one cell killing moiety.
9. A chimeric protein as claimed in claim 8, wherein said cell
killing moiety comprises Pseudomonas exotoxin A.
10. A chimeric protein as claimed in claim 8, that has no amino
acid between said cell killing moiety and said cell targeting
moiety.
11. A chimeric protein as claimed in claim 8, wherein said chimeric
protein recognizes and/or binds to GnRH-binding sites on
adenocarcinoma and hepatocarcinoma cells.
12. The chimeric protein of claim 8, wherein said cell targeting
moiety is Met-GnRH.
13. The chimeric protein of claim 8, wherein said cell targeting
moiety is a Met-GnRH analog.
14. The chimeric protein of claim 8, wherein said cell targeting
moiety is a Met-GnRH analog that includes Trp in a position
corresponding to GnRH position 6.
15. A chimeric protein comprising i) a Met proceeding GnRH or a
GnRH analog and ii) a peptide selected from the group consisting of
a) a mutated full length Pseudomonas exotoxin, and b) domains II
and III of the Pseudomonas exotoxin.
16. The chimeric protein of claim 21 wherein the chimeric protein
includes Met-GnRH-PE66.
17. The chimeric protein of claim 21 wherein the chimeric protein
includes Met-GnRH-PE40.
Description
FIELD OF THE INVENTION
[0001] The present invention relates generally to therapeutic
agents useful particularly in cancer targeted therapy but also in
treating malignant adenocarcinomas, such as breast, colon, hepatic,
ovarian and renal adenocarcinomas, and treating benign tumors of
the uterus, hyperplasia, endometriosis, BPH, polycystic disease of
the breast and pituitary adenomas.
[0002] More specifically, the said invention relates to Pseudomonas
exotoxin based chimeric toxins aimed at those neoplastic cells
bearing gonadotropin-releasing hormone binding sites. The present
invention further relates to pharmaceutical compositions comprising
as an active ingredient the above-mentioned neoplastic
cell-targeting chimeric toxins. Furthermore, the present invention
relates to a method for the production of said chimeric toxins.
These chimeric proteins, according to the present invention, are
comprised of cell-targeting moieties which consist of gonadotropin
releasing hormone homologues linked to cell-killing moieties which
consist, preferably, of the bacterial toxin Pseudomonas exotoxin A,
for recognizing and destroying neoplastic cells bearing
gonadotropin releasing hormone binding sites.
[0003] Targeting is a term for the selective delivery of
chemotherapeutic agents to specific cell populations. It is
possible to create chimeric molecules that possess cell-targeting
and cellular toxin domains. These chimeric molecules function as
cell selective poisons by virtue of their ability to target
selective cells and then kill those cells via their toxin
component. Pseudomonas exotoxin A (hereinafter called PE), a
bacterial toxin used in construction of such chimeric proteins,
acts by irreversibly arresting protein synthesis in eukaryotic
cells, resulting in cell death.
[0004] The term "gonadotropin releasing hormone homologues" in this
invention relates to the gonadotropin releasing hormone gene itself
or its analogues and antagonists. Also included in the scope of the
present invention are salts of the described chimeric proteins. The
term "salts" includes both salts of carboxy groups as well as acid
addition salts of amino groups of the protein molecule. The
invention further relates to pharmaceutical compositions comprising
the chimeric proteins as defined above together with a
pharmaceutically acceptable inert carrier. The proteins of the
present invention may be administered by methods known in the art
for the administration of proteins.
BACKGROUND OF THE INVENTION
[0005] Gonadotropin releasing hormone (hereinafter called GnRH)
participates in the hypothalamic--pituitary gonadal control of
human reproduction. The involvement of GnRH has been demonstrated
in several carcinomas and GnRH analogue treatment has been applied
in breast, prostatic, pancreatic, endometrial and ovarian cancers
(Kadar et al. Prostate 12:229-307, 1988). These analogues suppress
tumor cell growth in vitro and in vivo. The existence of GnRH
binding sites was revealed in the corresponding malignant cells and
in well-established cell lines (Emons et al. J. Clin. Endocrinol.
Metab. 77:1458-1464, 1993), though preliminary results suggest that
the GnRH receptor involved may differ from the previously
documented receptor (Kakar et al. Biochem. Biophys. Res. Comm.
189:289-295, 1992).
[0006] Although GnRH binding sites have been demonstrated in a
number of solid tumors and various carcinoma cell lines derived
mainly from hormone dependent tissues, their existence in colon or
renal carcinoma has not been previously documented. The presence of
specific GnRH binding sites in colon, breast, prostate, ovarian
endometrium, renal and liver carcinomas, is shown here.
Surprisingly, the specific GnRH binding sites are not limited to
hormone-dependant tissues, as indicated by the marked killing of
colon adenocarcinoma, renal cell adenocarcinoma and hepatocarcinoma
cells.
[0007] WO93/15751 describes various conjugates of GnRH, a linking
group and Pseudomonas exotoxin A, prepared using the techniques of
synthetic organic chemistry, used for the sterilization of animals
by killing gonadotropin releasing cells of the animals pituitary
gland.
[0008] The present invention describes the construction, by the
techniques of genetic engineering, of PE based chimeric toxins,
aimed at targeting those neoplastic cells bearing GnRH binding
sites. The chimeric toxins of the present invention are fusion
proteins and, as such, do not contain a chemical linking group (as
in the above-mentioned patent). Therefore, they are completely
different proteins from the molecules described in WO93/15751.
[0009] Using different kinds of targeting moieties, a large number
of immunotoxins have been generated in the last 20 years by
chemical linkage techniques or recombinant DNA technology. The size
of these targeting moieties varies widely, ranging from large
antibodies to small growth factors, cytokines and antibody
fragments.
[0010] The ability of large chimeric proteins, as the Met-GnRH-PE
constructions described in the present invention, to target cells
via a very small portion of the polypeptide (a peptide of ten amino
acids, as used as the targeting moiety of the present invention),
and yet retain their original functions, namely binding and
internalization, open up new possibilities in designing targeted
immunotoxins.
[0011] Colon, breast, and prostate cancer--three out of the four
major malignancies occurring in humans, together with ovarian,
endometrium, renal and liver carcinomas, account for more than 50%
of cancer related death. The presence of specific GnRH binding
sites in all of these cancers, may suggest a more general role of
GnRH and/or GnRH-like peptides in the malignant process.
[0012] Collectively, these results disclose what could be
considered the Achilles' heel of these malignant growths, a finding
that could open up new vistas in the fight against cancer.
[0013] In view of their efficient growth inhibition of the
above-mentioned cancer cells and their specificity regarding the
non-target cells, the novel Met-GnRH-PE chimeric toxins are
promising candidates for cancer treatment.
SUMMARY OF THE INVENTION
[0014] The present invention relates particularly to neoplastic
cell-targeting chimeric toxins comprising cell-targeting moieties
and cell-killing moieties for recognizing and for destroying the
neoplastic cells, wherein the cell-targeting moieties consist of
gonadotropin releasing hormone homologues and the cell-killing
moieties consist of Pseudomonas exotoxin A. The present invention
further relates to pharmaceutical compositions containing as an
active ingredient these neoplastic cell-targeting chimeric toxins
and to a method for the production of these chimeric toxins. The
said invention also relates to a method for cancer therapy,
treating malignant adenocarcinoma and hepatocarcinoma cells and
benign hyperplasia including uterine leiomyoma cells, extrauterine
endometrial island cells, benign hyperplasia of prostate and
breast, and pituitary tumor adenoma cells, by the use of the
above-mentioned chimeric toxins.
DETAILED DESCRIPTION OF THE INVENTION
[0015] The present invention describes Pseudomonas exotoxin A (PE)
based chimeric toxins constructed by ligating an oligonucleotide
encoding ten amino acids of a gonadotropin releasing hormone (GnRH)
analog (GnRH coding sequence with tryptophan replacing glycine as
the sixth amino acid), and a preceding Met (see FIG. 1C), upstream
of a mutated form of PE (domains I (mutated), II and III) thereby
generating Met-GnRH-PE66, and a ten amino acid synthetic GnRH
oligomer (GnRH coding sequence with tryptophan replacing glycine as
the sixth amino acid), with a preceding Met, ligated to domains II
and III of the PE, thereby generating Met-GnRH-PE40 protein.
[0016] The applications, potential markets and commercial
advantages of the said chimeric proteins according to the present
invention are listed:
[0017] There are two main applications:
[0018] 1) Malignant Adenocarcinomas and Hepatocarcinomas:
[0019] Breast, colon, ovarian and renal adenocarcinomas and
hepatocarcinoma were all sensitive to Met-GnRH-PE mediated
cytotoxicity. Thus, the potential market for this new chimeric
protein includes all adenocarcinoma and hepatocarcinoma patients,
either as a first line of treatment or for patients in which other
modalities of treatment had failed.
[0020] 2) Benign Tumors of the Uterus and Hyperplasia:
[0021] This group of pathologies includes various tissues that are
known to be sensitive to GnRH and thus can be targeted by the
Met-GnRH-PE chimeric proteins. [0022] a. Uterine:
[0023] Uterine leiomyoma is the most common benign tumor in women.
The uterine myomas are found to carry a large number of GnRH
receptors. GnRH analogs are clinically used for down-regulation and
shrinkage of these myomas. The disadvantage of GnRH analogs is that
these compounds cannot be used for long periods and the myomas
return to their original size after cessation of the treatment. The
use of Met-GnRH-PE for the destruction of the myomas can help to
avoid what was considered to be imminent hysterectomies. [0024] b.
Endometriosis--Endometrioma:
[0025] The existence of endometrial tissue out of the uterus leads
to the disease called endometriosis which can cause infertility,
abdominal pain and even surgical interventions. The endometrial
islands are known to be very sensitive to hormonal changes. One of
the therapeutic modalities found to be clinically efficient is the
GnRH analog. Using Met-GnRH-PE, these explants of endometrial
tissue can be eliminated, thereby helping infertile couples as well
as women who are undergoing laparotomy for the resection of these
endometrial islands. The treatment of both the leiomyoma and the
endometria can be administered systematically or locally by either
ultrasonic or laparoscopic guided injection into the peritoneal
cavity. [0026] c. Benign Prostatic Hyperplasia (BPH):
[0027] The prostatic cells are known to express GnRH receptors and
prostatic cancer is successfully treated today with GnRH agonists.
The BPH causes severe symptoms of dysuria, urinary retention and
sometimes can be treated only by prostatectomy. The use of
Met-GnRH-PE can therefore replace prostatectomy procedures carried
out on prostate hyperplasia that is not malignant. [0028] d.
Polycystic Disease of the Breast:
[0029] The mammary cells are also known to express the GnRH
receptors. As in the case of BPH, the polycystic disease of the
breast may be symptomatic, cause pain and may mimic breast
carcinoma. The use of Met-GnRH-PE may eliminate the need for
numerous check-ups and needless mammograms and help woman suffering
from breast pains and non-malignant breast tumors. [0030] e.
Pituitary Adenoma:
[0031] Some of the pituitary adenomas are derived from gonadotropic
cells. The pituitary adenoma, even though non-malignant, can cause
a grave prognosis by causing local pressure on vital organs (eyes,
brain stem). The trans-sphenoidal surgery used for the pituitary
adenoma has many disadvantages, including recurrency and
neurological sequela. Met-GnRH-PE may be aimed directly against the
gonadotropic cells without damaging other functions of the
pituitary gland. Met-GnRH-PE chimeric toxin may be administered
intrathecally.
[0032] Commercial Advantages:
[0033] 1. The wide variety of tumors that respond to the
Met-GnRH-PE chimeric protein.
[0034] 2. The high selectivity that allows a large therapeutic
range.
[0035] 3. The use of GnRH as a targeting peptide leaving the large
population of postmenopausal women in whom the GnRH has no
physiological role perfect candidates for the treatment.
[0036] 4. Its high specificity enables systemic administration
together with the local effect.
[0037] 5. The ability to eradicate small populations of cells in a
tissue that will not itself be harmed.
[0038] The proteins of the present invention may be administered by
methods known in the art for the administration of proteins. Also
included in the scope of the present invention are salts of the
described chimeric proteins. The term "salts" includes both salts
of carboxy groups as well as acid addition salts of amino groups of
the protein molecule. Salts of the carboxy group may be formed by
methods known in the art and include both inorganic salts as well
as salts with organic bases. The invention further relates to
pharmaceutical compositions comprising the chimeric proteins as
defined above together with a pharmaceutically acceptable inert
carrier. The pharmaceutical composition may be administered by
injection (intravenous, intra-articular, subcutaneous,
intramuscular, intrathecal or intraperitoneal) topical application,
oral administration, sustained release, or by any other route
including the enteral route.
[0039] The said invention will be further described in detail by
the following experiments and figures. These experiments and
figures do not intend to limit the scope of the invention but to
demonstrate and clarify it only.
DESCRIPTION OF THE FIGURES
[0040] FIGS. 1A-1C: Construction and expression of the
Met-GnRH-PE66 chimeric toxin. FIG. 1A, SDS-PAGE gel and FIG. 1B,
immunoblotting analysis of TGnRH-PE66 plasmid expression. Whole
cell extract of the lysed bacteria (lane 1). Soluble fraction (lane
2). Insoluble fraction (lane 3). FIG. 1C, construction of
TGnRH-PE66 plasmid. T7 promotor. GnRH analogue peptide.
Ampicillin.RTM.. PE664Glu. The numbers represent the corresponding
amino acids.
[0041] FIGS. 2A and 2B: The effect of increasing concentrations of
Met-GnRH-PE66 on various cell lines.
[0042] FIG. 2A: .box-solid. SW-48 colon adenocarcinoma, HepG2
hepatocarcinoma, .tangle-solidup. Caco2 colon adenocarcinoma.
[0043] FIG. 2B: OVCAR3 ovarian adenocarcinoma, HeLa cervix
adenocarcinoma, .largecircle. MDA MB-231 breast adenocarcinoma,
HT-29 colon adenocarcinoma.
[0044] FIGS. 3A-3F: The effect of Met-GnRH-PE66 on various primary
cultures. FIG. 3A, colon carcinoma primary cultures established
from three patients. FIG. 3B, renal cell carcinoma primary culture.
FIG. 3C, breast carcinoma primary cultures established from four
patients. FIG. 3D, ovarian carcinoma primary cultures established
from two patients. FIG. 3E, metastases of primary cultures
established from the corresponding patients represented in FIGS.
3A, 3C and 3D by the same symbols. FIG. 3F, control cells: #
leukocytes. bone marrow. fibroblasts. .gradient. colon.
[0045] FIGS. 4A-4B: Histopathological diagnosis of primary
cultures. FIG. 4A, anti-keratin positive staining of a colon
primary culture. FIG. 4B, anti-desmin negative staining of a colon
primary culture.
[0046] FIG. 5: Displacement of [.sup.125I] GnRH bound to membranes
of SW-48 cells by: .largecircle. Met-GnRH-PE66. .box-solid. GnRH
analogue (des-Gly.sup.10, [d-Ala.sup.6]-LHRH).
[0047] FIG. 6: Purification of Met-GnRH-PE66. Lane 1--protein
marker. Lane 2--whole cell extract. Lane 3--soluble fraction. Lane
4--insoluble fraction after refolding. Lane 5--after DEAE-Sepharose
column. Lane 6--after Sepharyl S-200 HR column.
[0048] FIG. 7: Purification of Met-GnRH-PE40: Lane 1--protein
marker. Lane 2--whole cell extract. Lane 3--soluble fraction. Lane
4--insoluble fraction after refolding. Lane 5--after DEAE-Sepharose
column. Lane 6--after Sepharyl S-200 HR column.
[0049] FIG. 8: Effects of Met-GnRH-PE chimeric proteins on SW-48
colon adenocarcinoma cell line:
[0050] .box-solid. Met-GnRH-PE66 insoluble fraction after
refolding.
[0051] .tangle-solidup. A Met-GnRH-PE66 purified protein.
[0052] Met-GnRH-PE40 purified protein.
EXPERIMENTS
Experiment 1. Met-GnRH-PE66 Chimeric Toxin Construction
[0053] A plasmid vector carrying the mutated full length PE gene
(pJY3A1136-1,3) (Chaudhary et al., J. Biol. Chem. 256:16306-16310,
1990) was cut with NdeI and Hind III. The insert was a 36 base pair
synthetic oligomer consisting of the GnRH coding sequence with
tryptophan replacing glycine as the sixth amino acid, and was
flanked by NdeI (5' end) and HindIII (3' end) restriction sites.
The resulting TGnRH-PE66 plasmid was confirmed by restriction
endonucleases digestion and DNA sequence analysis (FIG. 1C).
Experiment 2. TGnRH-PE40 Plasmid Construction
[0054] To construct the Met-GnRH-PE40 protein (Met-GnRH-domains II
and III of the PE), the TGnRH-PE66 plasmid vector (FIG. 1C) was
digested with NdeI and BamHI and ligated to a NdeI-BamHI 750 bp
fragment from the plasmid PHL-906 (Fishman et al., Biochemistry
33:6235-6243, 1994) along with an insert which is a 36 base pair
synthetic oligomer consisting of the GnRH coding sequence with
tryptophan replacing glycine as the sixth amino acid, flanked by
NdeI (5' end) and HindIII (3' end) restriction sites. The resulting
TGnRH-PE40 plasmid was confirmed by restriction endonuclease
digestion and DNA sequence analysis.
Experiment 3. Protein Expression
[0055] The protein expression method was the same for Met-GnRH-PE40
and Met-GnRH-PE66, unless mentioned. Escherichia coli strain BL21
(DE3) carrying the plasmid TGnRH-PE66 was grown in LB medium
containing ampicillin (100 .mu.g/ml) and Escherichia coli strain
BL21 (DE3) carrying the plasmid GnRH-PE40 was grown in Super-LB
medium containing ampicillin (50 .mu.g/ml). After reaching an A600
value of 1.5-1.7, the cultures were induced 90 minutes for
Met-GnRH-PE66 and overnight for Met-GnRH-PE40, at 37.degree. C.
with 1 mM isopropyl-d-thiogalactoside (IPTG). Cells were collected
by centrifugation and the pellet was incubated at -70.degree. C.
for several hours.
[0056] The frozen pellet was thawed and suspended in lysis buffer
(50 mM Tris HCl, pH 8.0, 1 mM EDTA and lysozyme 0.2 mg/ml),
followed by sonication (3.times.30 seconds) and centrifugation at
35,000.times.g for 30 minutes. The supernatant (soluble fraction)
was removed and the pellet (insoluble fraction) served as the
source for the chimeric proteins and for their purification.
[0057] Analysis of the insoluble fraction by SDS/PAGE gel
electrophoresis revealed a major band (70%) with an expected
molecular mass of 67 kDa, corresponding to the chimeric protein,
and two major unrelated bacterial proteins of 42 and 28 kDa (FIG.
1A). Immunoblotting with polyclonal antibodies against PE,
confirmed these data (FIG. 1B).
Experiment 4. Effect of the Met-GnRH-PE66 Chimeric Proteins on
Various Cell Lines
[0058] In the experiments described below, the insoluble fraction
of E. coli expressing cells was used as the source of the
Met-GnRH-PE66 chimeric protein.
[0059] The cytotoxic activity of Met-GnRH-PE66 was tested in
various established cell lines: SW-48 colon adenocarcinoma, HepG2
hepatocarcinoma, Caco2 colon adenocarcinoma, OVCAR3 ovarian
adenocarcinoma, HeLa cervix adenocarcinoma, MDA MB-231 breast
adenocarcinoma, HT-29 colon adenocarcinoma. Unless specified, all
cell lines were maintained in RPMI 1640 medium, cultured in 100 mm
Petri dishes in a humidified atmosphere of 5% CO.sub.2/95% air at
37.degree. C. HepG2 and Caco2 were maintained in Eagle's Minimal
Essential Medium, and HeLa cells were maintained in Dulbecco's
Modified Eagle's Medium. All media were supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 units/ml of penicillin and 100
.mu.g/ml streptomycin. On day 0, cells (10.sup.4 in 0.2 ml culture
medium) were seeded in 96 well tissue culture microplates and 24
hours later various concentrations of the Met-GnRH-PE66 were added.
After 24 hours incubation [.sup.3H]leucine [5 .mu.Ci per well] was
added for an additional 24 hours. At day 3, the plates were stored
at -70.degree. C. for several hours, followed by a quick thawing at
37.degree. C. Cells were harvested on filters and the incorporated
radioactivity was measured with a beta counter. The chimeric
protein was found to kill cells in a dose-dependent manner, with
considerable variation between cell lines (Table 1) ranging from
the strong response of HepG2 hepatocarcinoma, SW-48 and Caco2 colon
adenocarcinoma (FIG. 2A) to the intermediate one of OVCAR3 ovarian
adenocarcinoma, MDA MB-231 breast adenocarcinoma, HT-29 colon
adenocarcinoma, and HeLa cervix adenocarcinoma (FIG. 2B). Although
cytotoxicity was measured by inhibition of amino acid
incorporation, cell death was reflected in cell number and/or cell
necrosis 24 hours following the addition of the chimeric
protein.
[0060] To confirm the specificity of Met-GnRH-PE66 activity, two
other PE based recombinant proteins, expressed and extracted under
the same conditions, were used as controls. No substantial growth
inhibition was exerted by either PE664Glu, encoded by the mutated
full length PE gene, or by PIS2, an unrelated 80 bp sequence fused
to PE664Glu. When 15 .mu.g/ml of PE664Glu or PIS2 were added,
protein synthesis ranged from a slight increase to 20% inhibition
in the different cultures. Growth inhibition resulting from
treatment with one of the two proteins was considered
nonspecific.
[0061] The results are expressed as the percent of the control
experiments in which cells were not exposed to any protein (results
are summarized in Table 1 and in FIG. 2).
TABLE-US-00001 TABLE 1 Cytotoxic Activity of Met-GnRH-PE66 on
Various Cell Lines ID.sub.50 Cell Line Origin (.mu.g Total
Protein/Well)* Caco2 Colon adenocarcinoma 0.4 HT-29 Colon
adenocarcinoma 1.2 SW-48 Colon adenocarcinoma 0.3 OVCAR3 Ovarian
adenocarcinoma 3 MDA MB-231 Breast adenocarcinoma 2.3 HeLa Cervix
adenocarcinoma 1.8 HepG2 Hepatocarcinoma 0.3 *The ID.sub.50 values
show the effect of the insoluble fraction enriched with the
chimeric protein
Experiment 5. The Effect of Met-GnRH-PE66 on Various Primary
Cultures
[0062] In order to evaluate the cytotoxic effectiveness of the
chimeric proteins on cells resembling the original in vivo tumors
as closely as possible and to exclude the possibility that the
Met-GnRH-PE66 cytotoxicity was a characteristic developed by cells
upon prolonged passages, primary cultures were established.
[0063] Fresh tissue specimens were obtained from various cancer
patients undergoing therapeutic debulking procedures. Control
specimens were obtained from donors or patients undergoing
diagnostic or therapeutic procedures for non-malignant diseases.
All tissue specimens were washed several times with Leibovitz (L15)
medium, and extensively cut with a scalpel. The preparations were
then enzymatically proteolysed for 2 hours at 37.degree. C. with
gentle shaking in Leibovitz medium containing collagenase type I
(200 u/ml), hyaluronidase (100 u/ml), penicillin (1000 units/ml),
streptomycin (1 mg/ml), amphotericin B (2.5 .mu.g/ml) and
gentamycin (80 .mu.g/ml). Tissue preparations were centrifuged 10
minutes at 200.times.g and the pellets were suspended in RPMI 1640
medium, supplemented with 10% fetal calf serum, penicillin (100
u/ml) and streptomycin (100 .mu.g/ml) and plated in 100 mm Petri
dishes. Cells were grown for one to three weeks to a density of
8.times.10.sup.6 cells and histopathological diagnoses and
cytotoxic assays were performed. Normal leukocytes from peripheral
blood and bone marrow aspirates for cytotoxic assays were obtained
by diluting whole blood in one volume of phosphate-buffered saline.
The diluted sample was placed over an equal volume of Ficoll-Paque
and centrifuged for 10 minutes at 200.times.g. The cells were
resuspended and plated in RPMI 1640 medium containing 20% fetal
calf serum, 4 mM 1-glutamine, 50 .mu.M .beta.-mercaptoethanol,
non-essential amino acids, 1 mM sodium pyruvate, penicillin (100
units/ml) and streptomycin (100 .mu.g/ml).
[0064] The cytotoxic effect of the chimeric protein was variable
(Table 2) with up to three-fold differences in ID.sub.50 observed
in colon, breast and ovarian primary cultures originated from
different patients (FIGS. 3A, 3C and 3D respectively).
TABLE-US-00002 TABLE 2 Cytotoxic Effects of Met-GnRH-PE66 on
Various Primary Cultures ID.sub.50 Origin (.mu.g total
protein/well).sup.a Colon carcinoma 0.8-2.5.sup.b Renal cell
carcinoma 1.2 Breast carcinoma 1-3.sup.c Ovarian carcinoma
1.6-3.sup.d Bladder Carcinoma no effect control cells: Colon no
effect.sup.e Fibroblasts no effect.sup.e Bone marrow no
effect.sup.e Leukocytes no effect.sup.e .sup.aThe ID.sub.50 values
show the effect of the insoluble fraction enriched with the
chimeric protein .sup.bn = 3 .sup.cn = 4 .sup.dn = 2
.sup.eIncreasing concentration of Met-GnRH-PE66 did not affect cell
growth
[0065] In cases where metastasis biopsies could also be obtained,
cultures of primary tumors alongside with the metastasis were
examined for Met-GnPH-PE66 cytotoxicity. The metastatic cells
responded in the same manner, and their ID.sub.50 were even lower
than those of the primary tumors. This may be explained by the high
homogeneity of the metastasis culture compared with that of the
primary culture.
[0066] Met-GnRH-PE66 was also tested on cultures of benign colon
peripheral blood bone marrow and skin fibroblasts from healthy
donors. The addition of up to 15 .mu.g/ml of the chimeric protein
did not result in any measurable dose dependent killing (FIG.
3F).
Experiment 6. Histopathological Diagnosis of Primary Cultures
[0067] One of the basic questions regarding the veracity of the
primary culture assays is of the epithelial origin of the cells.
The tendency of cells in primary culture to lose their epithelial
morphology has been described in several carcinomas. To confirm the
absence of any substantial amount of "contaminating" fibroblasts,
differential staining was performed.
[0068] Cells were stained as follows: 10,000 cells were plated on a
microscope slide using a cytospin, followed by several minutes
incubation at room temperature. Dried slides were fixed by soaking
in -20.degree. C. cold methanol for 15 minutes and in -20.degree.
C. cold acetone for a few seconds. Slides were kept at -20.degree.
C. until staining. Staining was carried out with anti-desmin and
anti-keratin antibodies to distinguish fibroblast from epithelial
cells, respectively. This staining indicated that the vast majority
of the cells (80-100%) were indeed epithelial, even in cases where
the cultures exhibited a fibroblast-like shape (FIGS. 4A and
4B).
[0069] Further confirmation was achieved by staining with specific
antitumor marker antigens according to the type of cancer. Formalin
fixed sections from the original tumors and the primary cultures
cells displayed the same pattern and intensity of staining.
Experiment 7. Specific Binding by Met-GnRH-PE66
[0070] To support the findings that colon adenocarcinoma cell lines
and primary cultures can be targeted and killed by Met-GnRH-PE66,
the ability of plasma membrane fractions from a colon
adenocarcinoma cell line to specifically bind GnRH, was examined.
The addition of increasing concentrations of Met-GnRH-PE66 chimeric
toxin resulted in dose-related displacement of the .sup.125I-GnRH
bound to these membranes. A semiconfluent 100 mm dish of the SW-48
colon adenocarcinoma cell line was washed and the cells were
scraped off the plate with a rubber policeman. The collected cells
were homogenized in ice-cold assay buffer (10 mM Tris HCl, pH 7.6,
1 mM dithiothreitol, 0.15% bovine serum albumin, 1 mM EDTA) and
centrifuged at 250.times.g for 15 minutes (4.degree. C.). The
resulting pellet was discarded and the supernatant was centrifuged
at 20,000.times.g for 30 minutes (4.degree. C.). The plasma
membrane pellet was resuspended in cold assay buffer. Aliquots
containing 70 .mu.g plasma membrane protein in a final volume of
100 .mu.l, were incubated for 2 hours on ice with 6.times.10.sup.-6
M (240,000 cpm) .sup.125I-GnRH either in the presence or absence of
(10.sup.-4-10.sup.-10 M) unlabeled GnRH authentic peptide and
analog (des-Gly, [d-Ala]-LHRH) or (2.5.times.10.sup.-5-10.sup.-9 M)
Met-GnRH-PE66 chimeric toxin. Following incubation, samples were
washed through Whatman GF/C filters with 10 ml of cold assay buffer
and counted in a gamma counter.
[0071] The addition of increasing concentrations of Met-GnRH-PE66
chimeric toxin resulted in dose related displacement of the
.sup.125I-GnRH bound to these membranes. Unlabeled authentic GnRH
peptide and the analogue des-Gly10 [D-Ala6]-LHRH produced similar
results. As can be seen in FIG. 5, binding of the labeled GnRH to
SW-48 colon adenocarcinoma cell line was specific and displacement
by the Met-GnRH-PE66 chimeric toxin was as efficient as that by the
GnRH analogue peptide. There was 37% non-specific binding.
Experiment 8. Met-GnRH-PE40 and Met-GnRH-PE66 Purification
[0072] The pellet of the insoluble fraction was suspended and
stirred on ice in denaturation buffer (6 M guanidium HCl, 0.1 M
Tris HCl, pH 8.6, 1 mM EDTA, 0.05M NaCl and 10 mM DDT). After an
additional centrifugation, the reduced and denatured protein was
diluted 1:100 in refolding buffer (50 mM Tris HCl, pH 8, 1 mM EDTA,
0.25M NaCl, 0.25 M L-arginine and 5 mM DTT) and kept at 4.degree.
C. for 48 hours. Refolded protein solutions were diluted to 8 mM in
TE20 buffer (20 mM Tris, pH 8.0, 1 mM EDTA). DEAE Sepharose was
added and stirred for half an hour at 4.degree. C. before being
packed onto a column. Washing of the column was done with 80 mM
NaCl, in TE20 buffer for Met-GnRH-PE66 and 50 mM NaCl in TE20
buffer for Met-GnRH-PE40. Elution was performed with the linear
gradient of 2.times.200 ml of 0.08-0.35 M NaCl, in TE20 (20 mM
Tris, pH 8.0, 1 mM EDTA) buffer. The peak fractions were pooled,
0.5M L-arginine was added and stirred cell was used for
concentration. 3 ml of the pooled fractions from the ion exchange
column were loaded onto a Sepharyl S-200 HR gel filtration column,
in 0.5 M NaCl, 0.15 M K-phosphate buffer, pH 6.0. The peak
fractions were pooled, dialyzed against phosphate saline buffer and
kept in aliquots at -20.degree. C. Purification of Met-GnRH-PE66
and Met-GnRH-PE40 is demonstrated in FIGS. 6 and 7,
respectively.
Experiment 9. Effect of Highly-Purified Met-GnRH-PE Chimeric
Proteins on SW-48 Colon Adenocarcinoma Cell Line
[0073] The cytotoxic activity of the purified Met-GnRH-PE66 and
Met-GnRH-PE40 on the SW-48 colon adenocarcinoma cell line was
assessed by measuring the inhibition of protein synthesis. The
chimeric proteins were found to kill cells in a dose dependent
manner. The ID.sub.50 of the purified Met-GnRH-PE66 chimeric toxin
was two to three times lower than the refolded insoluble fraction.
The ID.sub.50 of the Met-GnRH-PE40 purified protein was three to
four times lower than the purified Met-(FIG. 8).
Sequence CWU 1
1
611152DNAEcherichia coli 1atggagcact ggtcctattg gctgcgccct
ggagaagctt ttgttaacgc ccatatggcc 60gaagagggcg gcagcctggc cgcgctgacc
gcgcaccagg cttgccacct gccgctggag 120actttcaccc gtcatcgcca
gccgcgcggc tgggaacaac tggagcagtg cggctatccg 180gtgcagcggc
tggtcgccct ctacctggcg gcgcggctgt cgtggaacca ggtcgaccag
240gtgatccgca acgccctggc cagccccggc agcggcggcg acctgggcga
agcgatccgc 300gagcagccgg agcaggcccg tctggccctg accctggccg
ccgccgagag cgagcgcttc 360gtccggcagg gcaccggcaa cgacgaggcc
ggcgcggcca acgccgacgt ggtgagcctg 420acctgcccgg tcgccgccgg
tgaatgcgcg ggcccggcgg acagcggcga cgccctgctg 480gagcgcaact
atcccactgg cgcggagttc ctcggcgacg gcggcgacgt cagcttcagc
540acccgcggca cgcagaactg gacggtggag cggctgctcc aggcgcaccg
ccaactggag 600gagcgcggct atgtgttcgt cggctaccac ggcaccttcc
tcgaagcggc gcaaagcatc 660gtcttcggcg gggtgcgcgc gcgcagccag
gacctcgacg cgatctggcg cggtttctat 720atcgccggcg atccggcgct
ggcctacggc tacgcccagg accaggaacc cgacgcacgc 780ggccggatcc
gcaacggtgc cctgctgcgg gtctatgtgc cgcgctcgag cctgccgggc
840ttctaccgca ccagcctgac cctggccgcg ccggaggcgg cgggcgaggt
cgaacggctg 900atcggccatc cgctgccgct gcgcctggac gccatcaccg
gccccgagga ggaaggcggg 960cgcctggaga ccattctcgg ctggccgctg
gccgagcgca ccgtggtgat tccctcggcg 1020atccccaccg acccgcgcaa
cgtcggcggc gacctcgacc cgtccagcat ccccgacaag 1080gaacaggcga
tcagcgccct gccggactac gccagccagc ccggcaaacc gccgcgcgag
1140gacctgaagt aa 11522383PRTEscherichia coli 2Met Glu His Trp Ser
Tyr Trp Leu Arg Pro Gly Glu Ala Phe Val Asn1 5 10 15Ala His Met Ala
Glu Glu Gly Gly Ser Leu Ala Ala Leu Thr Ala His20 25 30Gln Ala Cys
His Leu Pro Leu Glu Thr Phe Thr Arg His Arg Gln Pro35 40 45Arg Gly
Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu50 55 60Val
Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln65 70 75
80Val Ile Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly85
90 95Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu Ala Leu Thr
Leu100 105 110Ala Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly Thr
Gly Asn Asp115 120 125Glu Ala Gly Ala Ala Asn Ala Asp Val Val Ser
Leu Thr Cys Pro Val130 135 140Ala Ala Gly Ala Cys Ala Gly Pro Ala
Asp Ser Gly Asp Ala Leu Leu145 150 155 160Glu Arg Asn Tyr Pro Thr
Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp165 170 175Val Ser Phe Ser
Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu180 185 190Leu Gln
Ala His Arg Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly195 200
205Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly
Gly210 215 220Val Arg Ala Arg Ser Gln Asp Leu Asp Ala Ile Trp Arg
Gly Phe Tyr225 230 235 240Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
Tyr Ala Gln Asp Gln Glu245 250 255Pro Asp Ala Arg Gly Arg Ile Arg
Asn Gly Ala Leu Leu Arg Val Tyr260 265 270Val Pro Arg Ser Ser Leu
Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu275 280 285Ala Ala Pro Glu
Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro290 295 300Leu Pro
Leu Arg Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly305 310 315
320Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val
Val325 330 335Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn Val Gly
Gly Asp Leu340 345 350Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala
Ile Ser Ala Leu Pro355 360 365Asp Tyr Ala Ser Gln Pro Gly Lys Pro
Pro Arg Glu Asp Leu Lys370 375 38031869DNAEscherichisa coli
3atgcagcact ggtcctattg gctgcgccct ggagaagctt tcgacctctg gaacgaatgc
60gccaaagcct gcgtgctcga cctcaaggac ggcgtgcgtt ccagccgcat gagcgtcgac
120ccggccatcg ccgacaccaa cggccagggc gtgctgcact actccatggt
cctggagggc 180ggcaacgacg cgctcgagct ggccatcgac aacgccctca
gcatcaccag cgacggcctg 240accatccgcc tcgaaggcgg cgtcgagccg
aacaagccgc tgcgctacag ctacacgcgc 300caggcgcgcg gcaggtggtc
gctgaactgg ctggtaccga tcggccacga gaagccctcg 360aacatcaagg
tgttcatcca cgaactgaac gccggcaacc agctcagcca catgtcgccg
420atctacacca tcgagatggg cgacgagttg ctggcgaagc tggcgcgcga
tgccaccttc 480ttcgtcaggg cgcacgagag caacgagatg cagccgacgc
tcgccatcag ccatgccggg 540gtcagcgtgg tcatggccca gacccagccg
cgccgggaaa agcgctggag cgaatgggcc 600agcggcaagg tgttgtgcct
gctcgacccg ctggacgggg tctacaacta cctcgcccag 660caacgctgca
acctcgacga tacctgggaa ggcaagatct accgggtgct cgccggcaac
720ccggcgaagc atgacctgga catcaaaccc acggtcatca gtgaagagct
ggagtttccc 780gagggcggca gcctggccgc gctgaccgcg caccaggctt
gccacctgcc gctggagact 840ttcacccgtc atcgccagcc gcgcggctgg
gaacaactgg agcagtgcgg ctatccggtg 900cagcggctgg tcgccctcta
cctggcggcg cggctgtcgt ggaaccaggt cgaccaggtg 960atccgcaacg
ccctggccag ccccggcagc ggcggcgacc tgggcgaagc gatccgcgag
1020cagccggagc aggcccgtct ggccctgacc ctggccgccg ccgagagcga
gcgcttcgtc 1080cggcagggca ccggcaacga cgaggccggc gcggccaacg
ccgacgtggt gagcctgacc 1140tgcccggtcg ccgccggtga atgcgcgggc
ccggcggaca gcggcgacgc cctgctggag 1200gcgaactatc ccactggcgc
ggagttcctc ggcgacggcg gcgacgtcag cttcagcacc 1260cgcggcacgc
agaactggac ggtggagcgg ctgctccagg cgcaccgcca actggaggag
1320cgcggctatg tgttcgtcgg ctaccacggc accttcctcg aagcggcgca
aagcatcgtc 1380ttcggcgggg tgcgcgcgcg cagccaggac ctcgacgcga
tctggcgcgg tttctatatc 1440gccggcgatc cggcgctggc ctacggctac
gcccaggacc aggaacccga cgcacgcggc 1500cggatccgca acggtgccct
gctgcgggtc tatgtgccgc gctcgagcct gccgggcttc 1560taccgcacca
gcctgaccct ggccgcgccg gaggcggcgg gcgaggtcga acggctgatc
1620ggccatccgc tgccgctgcg cctggacgcc atcaccggcc ccgaggagga
aggcgggcgc 1680ctggagacca ttctcggctg gccgctggcc gagcgcaccg
tggtgattcc ctcggcgatc 1740cccaccgacc cgcgcaacgt cggcggcgac
ctcgacccgt ccagcatccc cgacaaggaa 1800caggcgatca gcgccctgcc
ggactacgcc agccagcccg gcaaaccgcc gcgcgaggac 1860ctgaagtaa
18694622PRTEscherichia coli 4Met Gln His Trp Ser Tyr Trp Leu Arg
Pro Gly Glu Ala Phe Asp Leu1 5 10 15Trp Asp Glu Cys Ala Lys Ala Cys
Val Leu Asp Leu Lys Asp Gly Val20 25 30Arg Ser Ser Arg Met Ser Val
Asp Pro Ala Ile Ala Asp Thr Asn Gly35 40 45Gln Gly Val Leu His Tyr
Ser Met Val Leu Glu Gly Gly Asn Asp Ala50 55 60Leu Glu Leu Ala Ile
Asp Asn Ala Leu Ser Ile Thr Ser Asp Gly Leu65 70 75 80Thr Ile Arg
Leu Glu Gly Gly Val Glu Pro Asn Lys Pro Leu Arg Tyr85 90 95Ser Tyr
Thr Arg Gln Ala Arg Gly Arg Trp Ser Leu Asn Trp Leu Val100 105
110Pro Ile Gly His Glu Lys Pro Ser Asn Ile Lys Val Phe Ile His
Glu115 120 125Leu Asn Ala Gly Asn Gln Leu Ser His Met Ser Pro Ile
Tyr Thr Ile130 135 140Glu Met Gly Asp Glu Leu Leu Ala Lys Leu Ala
Arg Asp Ala Thr Phe145 150 155 160Phe Val Arg Ala His Glu Ser Asn
Glu Met Gln Pro Thr Leu Ala Ile165 170 175Ser His Ala Gly Val Ser
Val Val Met Ala Gln Thr Gln Pro Arg Arg180 185 190Glu Lys Arg Trp
Ser Glu Trp Ala Ser Gly Lys Val Leu Cys Leu Leu195 200 205Asp Pro
Leu Asp Gly Val Tyr Asn Tyr Leu Ala Gln Gln Arg Cys Asn210 215
220Leu Asp Asp Thr Trp Glu Gly Lys Ile Tyr Arg Val Leu Ala Gly
Asn225 230 235 240Pro Ala Lys His Asp Leu Asp Ile Lys Pro Thr Val
Ile Ser Glu Glu245 250 255Leu Glu Phe Pro Glu Gly Gly Ser Leu Ala
Ala Leu Thr Ala His Gln260 265 270Ala Cys His Leu Pro Leu Glu Thr
Phe Thr Arg His Arg Gln Pro Arg275 280 285Gly Trp Glu Gln Leu Glu
Gln Cys Gly Tyr Pro Val Gln Arg Leu Val290 295 300Ala Leu Tyr Leu
Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val305 310 315 320Ile
Arg Asn Ala Leu Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly Glu325 330
335Ala Ile Arg Glu Gln Pro Glu Gln Ala Arg Leu Ala Leu Thr Leu
Ala340 345 350Ala Ala Glu Ser Glu Arg Phe Val Arg Gln Gly Thr Gly
Asn Asp Glu355 360 365Ala Gly Ala Ala Asn Ala Asp Val Val Ser Leu
Thr Cys Pro Val Ala370 375 380Ala Gly Glu Cys Ala Gly Pro Ala Asp
Ser Gly Asp Ala Leu Leu Glu385 390 395 400Ala Asn Tyr Pro Thr Gly
Ala Glu Phe Leu Gly Asp Gly Gly Asp Val405 410 415Ser Phe Ser Thr
Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu420 425 430Gln Ala
His Arg Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr435 440
445His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly
Val450 455 460Arg Ala Arg Ser Gln Asp Leu Asp Ala Ile Trp Arg Gly
Phe Tyr Ile465 470 475 480Ala Gly Asp Pro Ala Leu Ala Tyr Gly Tyr
Ala Gln Asp Gln Glu Pro485 490 495Asp Ala Arg Gly Arg Ile Arg Asn
Gly Ala Leu Leu Arg Val Tyr Val500 505 510Pro Arg Ser Ser Leu Pro
Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala515 520 525Ala Pro Glu Ala
Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu530 535 540Pro Leu
Arg Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg545 550 555
560Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val
Ile565 570 575Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn Val Gly Gly
Asp Leu Asp580 585 590Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala Ile
Ser Ala Leu Pro Asp595 600 605Tyr Ala Ser Gln Pro Gly Lys Pro Pro
Arg Glu Asp Leu Lys610 615 620514PRTArtificial SequenceSynthetic
sequence 5Met Glu His Trp Ser Tyr Trp Leu Arg Pro Gly Glu Ala Phe1
5 10645DNAArtificial SequenceSynthetic sequence 6catatggagc
actggtccta ttggctgcgc cctggagaag ctttc 45
* * * * *